Opdivo gains European approval for Hodgkin lymphoma
Latest approval for Opdivo good news, but won’t make up for lung cancer setback
Bristol-Myers Squibb/ Cancer/ News/ UK & Europe
Andrew McConaghie
Opdivo
0 Comment
Latest approval for Opdivo good news, but won’t make up for lung cancer setback
Articles/ Sales and Marketing/ UK & Europe/ Views and analysis
Andrew McConaghie
NHS England, NICE, Opdivo
0 Comment
NHS England will be able to control cost impact of NICE decisions more directly.
Andrew McConaghie
BMS, breakthrough, cancer, docetaxel, ESMO, kantar, Keytruda, Merck, Opdivo, Roche, Tecentriq, trial
0 Comment
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Andrew McConaghie
2016, cancer, development, ESMO, Keytruda, Opdivo, pharma, treatment
0 Comment
Despite Keytruda’s overwhelming victory, it’s not over yet in NSCLC
Cancer/ News/ R&D/ Sales and Marketing
Andrew McConaghie
BMS, immunotherapy, Nektar Therapeutics, NSCLC, Opdivo, PD-1
0 Comment
BMS and Nektar’s combination latest in frenzied immunotherapy field
Andrew McConaghie
BMS, immunotherapy, Keytruda, Merck, NSCLC, Opdivo
0 Comment
Merck steals a march on rival BMS.
Andrew McConaghie
BMS, immunotherapy, Oncology, Opdivo
0 Comment
BMS hopes combinations will maintain Opdivo lead after setback
Articles/ Cancer/ Pharma Market Access/ Views and analysis
Linda Banks
4-1BB, cancer, immuno-oncology, immunotherapy, Keytruda, Oncology, Opdivo, PD-1, R&D, T-cell
0 Comment
As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
Andrew McConaghie
Cosentyx, Imbruvica, melanoma, Opdivo, Quinsair, Scottish Medicines Consortium
0 Comment
Sanofi steals a march on rivals Amgen